13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. (April 2015) - Kenealy, M.; Benson, W.; Stevenson, W.; Eek, R.; Zantomio, D.; Cunningham, I.; Hiwase, D.; Cowan, L.; Vlachos, S.; Zannino, D.; Seymour, J.F.